Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 395

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial

Deng, Yanhong, Chi, Pan, Lan, Ping, Wang, Lei, Chen, Weiqing, Cui, Long, Chen, Daoda, Cao, Jie, Wei, Hongbo, Peng, Xiang, Huang, Zonghai, Cai, Guanfu, Zhao, Ren, Huang, Zhongcheng, Xu, Lin, Zhou, Hongfeng, Wei, Yisheng, Zhang, Hao, Zheng, Jian, Huang, Yan, Zhou, Zhiyang, Cai, Yue, Kang, Liang, Huang, Meijin, Peng, Junsheng, Ren, Donglin, Wang, Jianping·2016·Journal of Clinical Oncology

Abstract

Purpose: Total mesorectal excision with fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy is a standard treatment of locally advanced rectal cancer. This study investigated the addition of oxaliplatin with and without preoperative radiotherapy. Methods: In this multicenter, open-label, phase III trial, we randomly assigned (1:1:1) Chinese adults (age 18 to 75 years) with locally advanced stage II/III rectal cancer to three treatments: five 2-week cycles of infusional fluorouracil (leucovorin 400 mg/m 2, fluorouracil 400 mg/m 2, and fluorouracil 2.4 g/m 2 over 48 h) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 through 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m 2 on day 1 of each cycle (modified FOLFOX6 [mFOLFOX6]), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. Random assignment was performed by using computer-generated block randomization codes. The primary end point was 3-year disease-free survival. Secondary end points of histopathologic response and toxicity are reported. Results: A total of 495 patients were enrolled from June 2010 to February 2015; 475 were evaluable (fluorouracil-radiotherapy, n = 155; mFOLFOX6-radiotherapy, n = 157; mFOLFOX6, n = 163). In the fluorouracil-radiotherapy, mFOLFOX6-radiotherapy, and mFOLFOX6 groups, the rate of pathologic complete response (pCR) was 14.0%, 27.5%, and 6.6%, and downstaging (ypStage 0 to 1) was achieved by 37.1%, 56.4%, and 35.5% of patients, respectively. Higher toxicity and more postoperative complications were observed in patients who received radiotherapy. Conclusion: mFOLFOX6-based preoperative chemoradiotherapy results in a higher pCR rate than fluorouracil-based treatment. Perioperative mFOLFOX6 alone had inferior results and a lower pCR rate than chemoradiotherapy but led to a similar downstaging rate as fluorouracil-radiotherapy, with less toxicity and fewer postoperative complications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.66.6198

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 395

Metadata

Authors
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Chen, D., Cao, J., Wei, H., Peng, X., Huang, Z., Cai, G., Zhao, R., Huang, Z., Xu, L., Zhou, H., Wei, Y., Zhang, H., Zheng, J., Huang, Y., Zhou, Z., Cai, Y., Kang, L., Huang, M., Peng, J., Ren, D., & Wang, J.
Venue
Journal of Clinical Oncology
Published
2016-09-20
Volume
34
Issue
27
Pages
3300-3307
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2492618519
Cited by
395
References
24
FWCI
18.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. https://app.cochat.ai/papers/10.1200/jco.2016.66.6198
The paper
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Chen, D., Cao, J., Wei, H., Peng, X., Huang, Z., Cai, G., Zhao, R., Huang, Z., Xu, L., Zhou, H., Wei, Y., Zhang, H., Zheng, J., . . . Wang, J. (2016). Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.66.6198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.